Impact of venous thromboembolism in hospitalized patients with pancreatic cancer: A nationwide inpatient sample (NIS) study.

Authors

null

Nishanth Thalambedu

UAMS Myeloma Center, Little Rock, AR

Nishanth Thalambedu , Waqas Ullah , Sravani Gundarlapalli

Organizations

UAMS Myeloma Center, Little Rock, AR, Thomas Jefferson University Hospital, Philadelphia, PA

Research Funding

No funding received

Background: Pancreatic cancer (PC) has a strong association with venous thromboembolism (VTE) but the impact of it on mortality and morbidity is unknown. Inpatient costs contribute significantly to the overall cancer care costs even though there is a modest improvement in survival of pancreatic cancer patients. This study aims to determine the mortality trends and associated health care utilization in PC patients with and without VTE and to analyze its impact on hospitalized patients. Methods: We used National Inpatient Sample (NIS) to extract data for all patients above 18years of age hospitalized with a primary diagnosis of Pancreatic cancer from 2002-2018 using ICD-9 and ICD-10 codes. Unadjusted odds ratio for dichotomous outcomes were calculated, and independent t test analysis was done for continuous outcomes. Results: The odds of all-cause mortality (OR 1.35, 95% CI 1.33-1.37, p<0.001) and stroke (OR 1.82, 95% CI, 1.76-1.87, p<0.001) were significantly higher in pancreatic cancer patients with VTE compared to without VTE. PC patients with VTE were found to have significantly higher average cost of hospitalization (US $56101 vs US $46325, p<0.001) and longer length of stay(LOS) (8.20 vs 6.83, p<0.001) when compared to patients without VTE. Conclusions: Hospitalized PC patients with VTE have higher odds of mortality and stroke when compared to PC patients without VTE. Similarly, VTE in PC patients is shown to increase the hospitalization costs and overall length of stay.

In-Hospital outcomes of all patients with pancreatic cancer without VTE and with VTE. Comparison of in-patient outcomes of continuous variables on Mann-Whitney U test analysis.

Variable

No VTE
VTE
uOR (95% CI)
p=value
Mortality
186199 (9.1%)
20439 (11.8%)
1.35 (1.33-1.37)
<0.0001
Stroke
34628 (1.7%)
5216 (3%)
1.82 (1.76-1.87)
<0.0001
Continuous Variables
No VTE (2058088)
VTE(173028)
P-value
Length of stay
6.83 ± 6.997
8.20 ± 8.391
<0.0001
Total charges
46325.59 ± 66711.056
56101.0± 85275.526
<0.0001

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

DOI

10.1200/JCO.2022.40.4_suppl.535

Abstract #

535

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts

First Author: Arun Kumar

Abstract

2023 ASCO Annual Meeting

In-hospital outcomes of patients with pancreatic cancer and venous thromboembolism.

First Author: Ankushi Sanghvi

First Author: Alekhya Pagidipally